Alpha Teknova/$TKNO
1D1W1MYTD1Y5YMAX
Capital at risk
About Alpha Teknova
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
- Ticker
- $TKNO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 158
- Headquarters
- Hollister, United States
- Website
- www.teknova.com
Alpha Teknova Metrics
BasicAdvanced
$448M
-
-$0.31
0.68
-
Price and volume
Market cap
$448M
Beta
0.68
52-week high
$8.38
52-week low
$1.91
Average daily volume
263K
Financial strength
Current ratio
4.485
Quick ratio
3.324
Long term debt to equity
0.407
Total debt to equity
0.438
Interest coverage (TTM)
-17.56%
Profitability
EBITDA (TTM)
-8.973
Gross margin (TTM)
34.60%
Net profit margin (TTM)
-38.37%
Operating margin (TTM)
-35.04%
Effective tax rate (TTM)
-0.56%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-9.28%
Return on equity (TTM)
-24.19%
Valuation
Price to revenue (TTM)
10.224
Price to book
7.15
Price to tangible book (TTM)
8.73
Price to free cash flow (TTM)
-60.764
Free cash flow yield (TTM)
-1.65%
Free cash flow per share (TTM)
-0.137
Growth
Revenue change (TTM)
12.27%
Earnings per share change (TTM)
-22.76%
3-year revenue growth (CAGR)
3.66%
3-year earnings per share growth (CAGR)
-44.55%
Bulls say / Bears say
Second quarter 2026 revenue reached $12.2 million, up 18% year-over-year to the highest quarterly total in company history, demonstrating robust demand for Teknova’s critical reagents (SEC filing)
Lifting full-year 2026 outlook to $45–47 million in revenue and cutting expected free cash outflow to under $8 million underscores management’s confidence in sustained growth and improved cash generation (SEC filing)
Launch of the Build-Tek™ AI-powered custom order configurator in Q2 accelerates customer product development cycles from weeks to minutes, enhancing Teknova’s differentiation and potential market share gains (SEC filing)
Net loss of $3.2 million in Q2 2026, with a negative $0.06 per diluted share, indicating the company remains unprofitable despite record revenue growth (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
Alpha Teknova News
AllArticlesVideos
Funds containing Alpha Teknova
AllUSDGBPEUR
Fund name | Fund size | $TKNO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.03% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.